Maturation and Trafficking Markers on Rotavirus-Specific B Cells during Acute Infection and Convalescence in Children

Jaimes, Martha; Rojas, Olga L.; Kunkel, Eric J.; Lazarus, Nicole H.; Soler, Dulce; Butcher, Eugene C.; Bass, Dorsey; Ángel, Juana; Franco, Manuel; Greenberg, Harry B.

doi:10.1128/jvi.78.20.10967-10976.2004

Cited by 68 publications

(70 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ϩ IgG ϩ and CD27 Ϫ IgG ϩ cells further suggest that these cells could be distinct in relation to the nature of the Ags and the outcome of the immunological response, as already proposed for the rotavirus-specific B cell response (29,80). CD27 can be triggered by its ligand, CD70, which is expressed on activated B and T cells (69,81,82).…”

Section: Figure 4 Expression Of Cd126 Is Higher In Cd27mentioning

confidence: 55%

A New Memory CD27−IgG+ B Cell Population in Peripheral Blood Expressing VH Genes with Low Frequency of Somatic Mutation

Fecteau

Côté

Néron

2006

The Journal of Immunology

269

254

View full text Add to dashboard Cite

In humans, up to 40% of peripheral B cells express CD27 and have hypermutated variable regions in their Ig genes. The CD27+ B cells are considered to be derived from germinal center following specific antigenic stimulation. Actually, somatic hypermutation in Ig genes and CD27 expression are hallmarks of memory B cells. However, the blood IgM+IgD+CD27+ B cells were recently associated to splenic marginal zone B cells and proposed to be a subset distinct from germinal center-derived memory B cells showing premutated Igs. The results presented herein further weaken this bona fide association because B cells expressing surface IgG, but not CD27, were found in human blood. Representing 1–4% of all peripheral B cells and ∼25% of the IgG+ blood B cells, this population expressed mutated IgG genes showing antigenic selection characteristics but with lower mutation frequencies than that of CD27+IgG+ B cells. However, their morphology and phenotype were similar to that of CD27+IgG+ cells. Interestingly, the proportion of IgG2 over IgG3 transcripts was opposite in CD27−IgG+ and CD27+IgG+ cells, suggesting distinct functions or origins. Overall, these findings extend the memory B cell reservoir beyond the CD27+ compartment and could provide further insights into B cell disorders of unknown etiology.

show abstract

Section: Figure 4 Expression Of Cd126 Is Higher In Cd27mentioning

confidence: 55%

A New Memory CD27−IgG+ B Cell Population in Peripheral Blood Expressing VH Genes with Low Frequency of Somatic Mutation

Fecteau

Côté

Néron

2006

The Journal of Immunology

269

254

View full text Add to dashboard Cite

show abstract

“…However, compared to results obtained with the same method, our results show that a4b7 expression by RV-specific B lymphocytes induced by i.n. administered nonreplicating Ag is lower than that observed in intestinal lymphoid tissues after oral administration of live virus in mice [15] (in this case up to 50% and 60% of RV-specific extrafollicular B cells expressed a4b7 in PP and MLN, respectively) or during an acute infection in children and adults [20,24]. This result suggests that a4b7 expression may probably not be a critical requirement for protection against RV infection after i.n.…”

Section: Igdmentioning

confidence: 84%

Distribution and phenotype of murine rotavirus-specific B cells induced by intranasal immunization with 2/6 virus-like particles

et al. 2005

View full text Add to dashboard Cite

Virus-like particles containing the rotavirus (RV) internal proteins VP2 and VP6 (2/6-VLP) have been shown to induce serum and fecal antibodies as well as protection in mice after intranasal administration with a mutant of E. coli toxin, LT-R192G. To better understand the origin of fecal IgA induced by this protocol, we studied the RV-specific B cell response in systemic and mucosal lymphoid tissues using a flow cytometry assay that allows quantification and phenotypic characterization of RV-specific B lymphocytes. We also assessed the RV-specific antibody-secreting cells in the spleen and intestinal lamina propria (ILP). A remarkably high frequency of RV-specific B cells was found in the respiratory lymphoid tissues and spleen, of which only a minority expressed the a4b7 integrin (intestinal homing receptor). In contrast, but in accordance with a4b7 expression at the induction site, a very low response was observed in intestinal lymphoid tissues (mesenteric lymph nodes and ILP), which did not increase after a second immunization. Thus, intranasal immunization with a nonreplicating antigen does not induce an important number of RV-specific B cells with an intestinal homing profile.

show abstract

“…During an acute RV infection in children, circulating IgD-RV-mBc express intestinal-homing receptors (a4b7C, CCR9C), and thus probably reflect mucosal immunity. 87 In a trial of the attenuated human RV1 vaccine precursor, when vaccines and placebo recipients were analyzed jointly, a very weak correlation was found between a4b7C, CCR9C IgD-circulating RV-mBc and protection. 75 Studies are underway to better understand and quantify RV-mBc.…”

Section: Rv-specific Antibody Secreting Cells (Asc) and Memory B Cellsmentioning

confidence: 99%

Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges

Ángel

Steele

Franco

2014

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Rotavirus (RV) is a major vaccine-preventable killer of young children worldwide. Two RV vaccines are globally commercially available and other vaccines are in different stages of development. Due to the absence of a suitable correlate of protection (CoP), all RV vaccine efficacy trials have had clinical endpoints. These trials represent an important challenge since RV vaccines have to be introduced in many different settings, placebo-controlled studies are unethical due to the availability of licensed vaccines, and comparator assessments for new vaccines with clinical endpoints are very large, complex, and expensive to conduct. A CoP as a surrogate endpoint would allow predictions of vaccine efficacy for new RV vaccines and enable a regulatory pathway, contributing to the more rapid development of new RV vaccines. The goal of this review is to summarize experiences from RV natural infection and vaccine studies to evaluate potential CoP for use as surrogate endpoints for assessment of new RV vaccines, and to explore challenges and opportunities in the field.

show abstract

Maturation and Trafficking Markers on Rotavirus-Specific B Cells during Acute Infection and Convalescence in Children

Cited by 68 publications

References 41 publications

A New Memory CD27−IgG+ B Cell Population in Peripheral Blood Expressing VH Genes with Low Frequency of Somatic Mutation

A New Memory CD27−IgG+ B Cell Population in Peripheral Blood Expressing VH Genes with Low Frequency of Somatic Mutation

Distribution and phenotype of murine rotavirus-specific B cells induced by intranasal immunization with 2/6 virus-like particles

Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges

Contact Info

Product

Resources

About